

Aspects of Decision Making in Cost-effectiveness Modelling

Nathan Green (n.green@ucl.ac.uk)

(with thanks to Gianluca Baio, Chris Jackson, Nicky J. Welton, Mark Strong, Anna Heath)

24th November 2022


I

Preliminaries



- UCL was rated 2nd in the UK for research power in the Research Excellence Framework 2021
- UCL is ranked 8th in the 2022 QS World University Rankings
- The Department of Statistical Science has played a major role in the development of the subject ever since its foundation in 1911 as the Department of Applied Statistics

Lectures



- Introduction to *Health economics modelling*
 - ▶ Decision trees
 - ▶ Markov models
- Introduction to sensitivity analyses
 - ▶ Deterministic
 - ★ One-way & multi-way
 - ★ Scenario
 - ▶ Probabilistic

Computer practicals



- Emphasis on practical examples
 - ▶ Decision tree and Markov models
 - ▶ using R programming language

- 0:00-1:00 Health Economics modelling lecture
- 1:00 - 1:45 Decision tree and Markov model practical
- BREAK
- 1:50 - 2:20 Sensitivity analysis
- 2:20-3:00 Sensitivity analysis practical

Books



- This course is only a small part of an *annual week-long summer school*
 - ▶ usually in Florence, Italy
- Several books available
- Edition two of BCEA book in the pipeline and a Health Economic in R book close to being finished!

Lecture 2

Uncertainty analysis

- XXX

References

Bayesian Methods in Health Economics, chapter 1.

Baio et al (2017). *Bayesian Cost-Effectiveness Analysis with the R package BCEA*

- XXX

References

Bayesian Methods in Health Economics, chapter 1.

Baio et al (2017). *Bayesian Cost-Effectiveness Analysis with the R package BCEA*

- XXX

References





Bayesian Methods in Health Economics, chapter 1.

Baio et al (2017). *Bayesian Cost-Effectiveness Analysis with the R package BCEA*

4. Uncertainty analysis


$$[p(\theta | e, c) \text{ vs } g_i(\theta_i)]$$

Parameters




Model structure

Old chemotherapy



New chemotherapy



Decision analysis


Old chemotherapy	
Benefits	Costs

New chemotherapy	
Benefits	Costs

4. Uncertainty analysis


$$[p(\theta | e, c) \text{ vs } g_i(\theta_i)]$$

Parameters




Model structure

Old chemotherapy



New chemotherapy



Decision analysis

Old chemotherapy	
Benefits	Costs

--	--

New chemotherapy	
Benefits	Costs

--	--





--	--

--	--

4. Uncertainty analysis


$$[p(\theta \mid e, c) \text{ vs } g_i(\theta_i)]$$

Parameters




Model structure

Old chemotherapy



New chemotherapy



Decision analysis


Old chemotherapy	
Benefits	Costs

New chemotherapy	
Benefits	Costs

4. Uncertainty analysis


$$[p(\theta | e, c) \text{ vs } g_i(\theta_i)]$$

Parameters




Model structure

Old chemotherapy



New chemotherapy



Decision analysis

Old chemotherapy	
Benefits	Costs

--	--

New chemotherapy	
Benefits	Costs





--	--

--	--

4. Uncertainty analysis


$$[p(\theta \mid e, c) \text{ vs } g_i(\theta_i)]$$

Parameters




Model structure

Old chemotherapy



New chemotherapy



Decision analysis





Old chemotherapy	
Benefits	Costs
741	670 382.1

New chemotherapy	
Benefits	Costs
732	1 131 978

4. Uncertainty analysis


$$[p(\theta | e, c) \text{ vs } g_i(\theta_i)]$$

Parameters




Model structure

Old chemotherapy



New chemotherapy



Decision analysis





Old chemotherapy	
Benefits	Costs
741	670 382.1
699	871 273.3

New chemotherapy	
Benefits	Costs
732	1 131 978
664	1 325 654

4. Uncertainty analysis


$$[p(\theta \mid e, c) \text{ vs } g_i(\theta_i)]$$

Parameters




Model structure

Old chemotherapy



New chemotherapy



Decision analysis

Old chemotherapy	
Benefits	Costs
741	670 382.1
699	871 273.3
...	...
726	425 822.2
716.2	790 381.2

New chemotherapy	
Benefits	Costs
732	1 131 978
664	1 325 654
...	...
811	766 411.4
774.5	1 066 849.8

$$\text{ICER} = \frac{276\,468.6}{58.3} = 6\,497.1$$

- The CEAC only deals with the **probability** of making the “right decision”
- But it does not account for the **payoff/penalty** associated with making the “wrong” one!

- The CEAC only deals with the **probability** of making the “right decision”
- But it does not account for the **payoff/penalty** associated with making the “wrong” one!
- **Example 1:** Intervention $t = 1$ is the most cost-effective, given current evidence
 - ▶ $\Pr(t = 1 \text{ is cost-effective}) = 0.51$
 - ▶ If we get it wrong: Increase in costs = £3
Decrease in effectiveness = 0.000001 QALYs
 - ▶ **Large uncertainty/negligible consequences** \Rightarrow **can afford uncertainty**

- The CEAC only deals with the **probability** of making the “right decision”
- But it does not account for the **payoff/penalty** associated with making the “wrong” one!
- **Example 1:** Intervention $t = 1$ is the most cost-effective, given current evidence
 - ▶ $\Pr(t = 1 \text{ is cost-effective}) = 0.51$
 - ▶ If we get it wrong: Increase in costs = £3
Decrease in effectiveness = 0.000001 QALYs
 - ▶ **Large uncertainty/negligible consequences** \Rightarrow **can afford uncertainty**
- **Example 2:** Intervention $t = 1$ is the most cost-effective, given current evidence
 - ▶ $\Pr(t = 1 \text{ is cost-effective}) = 0.999$
 - ▶ If we get it wrong: Increase in costs = £1 000 000 000
Decrease in effectiveness = 999999 QALYs
 - ▶ **Tiny uncertainty/dire consequences** \Rightarrow **probably should think about it...**